Sarepta Therapeutics, Inc. SRPT Deferred revenue, net of current portion
Deferred revenue, net of current portion at other companies
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sarepta Therapeutics, Inc.'s deferred revenue, net of current portion.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sarepta Therapeutics, Inc.'s deferred revenue, net of current portion?
- Sarepta Therapeutics, Inc. (SRPT) reported deferred revenue, net of current portion of $136.35M in Q1 2026.
- How has Sarepta Therapeutics, Inc.'s deferred revenue, net of current portion changed year-over-year?
- Sarepta Therapeutics, Inc.'s deferred revenue, net of current portion decreased by 58.0% year-over-year, from $325M to $136.35M.
- What is the long-term trend for Sarepta Therapeutics, Inc.'s deferred revenue, net of current portion?
- Over 5 years (2020 to 2025), Sarepta Therapeutics, Inc.'s deferred revenue, net of current portion has grown at a -33.9% compound annual growth rate (CAGR), from $663.49M to $83.91M.